Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 398

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 398
---
umab. Dr. Wolfgang Wick, the principal investigator for the Phase I clinical trial, also conducted this combination study. This Phase I/II clinical trial was not sized or designed to yield advanced comparative statistical results. Larger patient cohorts and additional design features typical of Phase 2/PoC studies (including randomization, Blinding, control groups) are required to obtain data yielding advanced statistics and guide the design of registrational (Ph3) studies. Assuming the Transaction is completed in the first half of 2025, initiation of such trials is planned for 2026. VXM01 Phase I clinical trial — Patient selection criteria Patients were selected by a third party clinical trial provider, each of whom met the following criteria: • Diagnosis:anaplastic astrocytoma (WHO Grade III) or glioblastoma (WHO Grade IV) located above the tentorium cerebelli in the brain. • Age:18 years or older. • Sex:men or women who were post -menopausalfor at least 2 years or surgically sterile. • Disease progression:evidence of tumor growth after at least one treatment regimen containing radiation and temozolomide chemotherapy. • Resectable tumor:eligible for a repeat surgery to remove the tumor, with the surgery able to be delayed for 30 days. • General health:good bone marrow, liver, and kidney function (as determined by blood and urine tests); able to undergo MRI scans; no active infection at the time of vaccination; Karnofsky performance status greater than 70; and adequate blood counts. • No recent clinical trials:no participation in another clinical trial within 30 days before screening. • No specific infections:negative test results for Hepatitis B, Hepatitis C, and HIV. • No interfering conditions:no other medical or social conditions that might interfere with the study or make it unsafe for the patient to participate. The study included 14 white patients with a mean age of 56.8 years. The majority of participants (64.3%) were male.

245

VXM01 phase I clinical trial — Tumor response The tumor response was assessed by objective response rate (ORR) according to immunotherapy Response Assessment for Neuro -Oncology(iRANO; 2015). Overall, the tumor response to VXM01 was mixed, with some patients showing signs of stable disease or even tumor shrinkage, while others experienced disease progression. These findings highlight the variability in treatment response and the challenges of managing glioblastoma. The extension